DS
KNTE

David Shaw’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

David Shaw’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-150,695
Closed -$357K – 4853
2023
Q4 		$357K Buy
150,695
+94,885
+170% +$168K ﹤0.01% 3676
2023
Q3 		$78.1K Sell
55,810
-4,299
-7% -$10.3K ﹤0.01% 3878
2023
Q2 		$182K Buy
+60,109
New +$232K ﹤0.01% 3758
2022
Q1 		– Sell
-13,989
Closed -$248K – 6071
2021
Q4 		$248K Sell
13,989
-14,479
-51% -$305K ﹤0.01% 4776
2021
Q3 		$655K Buy
28,468
+7,711
+37% +$168K ﹤0.01% 3907
2021
Q2 		$483K Sell
20,757
-2,088
-9% -$53.1K ﹤0.01% 4054
2021
Q1 		$712K Buy
+22,845
New +$796K ﹤0.01% 3326

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

David Shaw's KNTE Position: Q1 2024 in Review

David Shaw sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2024, closing a stake of 150,695 shares — an estimated $357K sold.

David Shaw first reported a position in KNTE in Q1 2021 and held it in 7 quarters. The position peaked at $712K in Q1 2021. 56 funds tracked by Wall St. Rank hold KNTE as of Q1 2024.

  • David Shaw reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • David Shaw sold 150,695 Kinnate Biopharma Inc. Common Stock shares in Q1 2024, an estimated $357K.
  • David Shaw first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 7 quarters.
  • David Shaw's Kinnate Biopharma Inc. Common Stock position peaked at $712K in Q1 2021.
  • 56 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.